The Leber Congenital Amaurosis (LCA) drugs in development market research report provides comprehensive information on the therapeutics under development for Leber Congenital Amaurosis (LCA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Leber Congenital Amaurosis (LCA). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Leber Congenital Amaurosis (LCA) and features dormant and discontinued products.
GlobalData tracks 20 drugs in development for Leber Congenital Amaurosis (LCA) by 16 companies/universities/institutes. The top development phase for Leber Congenital Amaurosis (LCA) is preclinical with 11 drugs in that stage. The Leber Congenital Amaurosis (LCA) pipeline has 17 drugs in development by companies and three by universities/ institutes. Some of the companies in the Leber Congenital Amaurosis (LCA) pipeline products market are: Opus Genetics, Variant and MeiraGTx.
The key targets in the Leber Congenital Amaurosis (LCA) pipeline products market include Retinoid Isomerohydrolase, Centrosomal Protein Of 290 kDa, and Cone Rod Homeobox Protein.
The key mechanisms of action in the Leber Congenital Amaurosis (LCA) pipeline product include Retinoid Isomerohydrolase Activator with four drugs in Phase II. The Leber Congenital Amaurosis (LCA) pipeline products include three routes of administration with the top ROA being Intraocular and three key molecule types in the Leber Congenital Amaurosis (LCA) pipeline products market including Gene Therapy, and Antisense Oligonucleotide.
Leber Congenital Amaurosis (LCA) overview
Leber congenital amaurosis (LCA) is a genetic eye disorder that primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment.
For a complete picture of Leber Congenital Amaurosis (LCA)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
